In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains

International Journal of Pharmaceutics

Volumn 315, Issue 1-2, 2006, Pages 59-66

  Drulis Kawa, Zuzanna ^a,b   Gubernator, Jerzy ^a,c   Dorotkiewicz Jach, Agata ^a   Doroszkiewicz, Wlodzimierz ^a   Kozubek, Arkadiusz ^a  

^a UNIVERSITY OF WROC AW   (Poland)

^b Lower Silesian Centre of Paediatrics in Wroclaw   (Poland)

^c Academic Centre for the Biotechnology of Lipid Aggregates   (Poland)

Author keywords

Liposomes; Meropenem; Pseudomonas aeruginosa

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 1,2 DIOLEOYLGLYCERO 3 PHOSPHOETHANOLAMINE; 1,2 DISTEAROYLGLYCERO 3 PHOSPHOCHOLINE; ANION; CATION; CHOLESTEROL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; ETHANOLAMINE; FLUIDOSOMES; LIPID; LIPOSOME; MEROPENEM; OCTADECYLAMINE; PHOSPHATIDYLCHOLINE; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; DRUG SENSITIVITY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-INFECTIVE AGENTS; DRUG CARRIERS; DRUG RESISTANCE, MICROBIAL; LIPOSOMES; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 33646373212     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.02.017     Document Type: Article

References (33)

1. Bakker-Woudenberg I.A.J.M. Delivery of antimicrobials to infected tissue macrophages. Adv. Drug Deliv. Rev. 17 (1995) 5-20
2. Beaulac C., Clement-Major S., Hawari J., and Lagace J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob. Agents Chemother. 40 (1996) 665-669
3. Beaulac C., Sachetelli S., and Lagace J. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gram-negative and Gram-positive bacteria. J. Antimicrob. Chemother. 41 (1998) 35-41
4. Bodey G.P., Bolivar R., Fainstein V., and Jadeja L. Infection caused by Pseudomonas aeruginosa. Rev. Infect. Dis. 5 (1983) 279-313
5. Carmeli Y., Castro J., Eliopoulos G.M., and Samore M.H. Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam. Antimicrob. Agents Chemother. 45 (2001) 275-279
6. Deol P., and Khuller G.K. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta 1334 (1997) 161-172
7. Emori T.G., and Gaynes R.P. An overview of nosocomial infections, including the role of microbiology laboratory. Clin. Microbiol. Rev. 4 (1993) 428-442
8. Fung-Tomc J.C., Huczko E., Banville J., Menard M., Kolek B., Gradelski E., Kessler R.E., and Bonner D.P. Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39 (1995) 394-399
9. Livermore D.M. Of Pseudomonas, porins, pumps and carbapenems. J. Antimicrob. Chemother. 47 (2001) 247-250
10. Livermore D.M., and Woodford N. Carbapenemases: a problem in waiting?. Curr. Opin. Microbiol. 3 (2000) 489-495
11. Lutwyche P., Cordeiro C., Wiseman D.J., St. Louis M., Uh M., Hope M.J., Webb M.S., and Finlay B.B. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob. Agents Chemother. 42 (1998) 2511-2520
12. Masuda N., Sakagawa E., and Ohya S. Outer membrane protein responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39 (1995) 645-649
13. Mayon-White R.T., Ducel G., and Kereselidze T. An international survey of the prevalence of hospital-aquired infection. J. Hosp. Infect. 2 (1988) 43-48
14. Mehta R.T., Keyhani A., McQueen T.J., Rosenbaum B., Rolston K.V., and Tarrand J.J. In vitro activities of free and liposomal drugs against Mycobacterium avium, M. intracellulare complex and M. tuberculosis. Antimicrob. Agents Chemother. 37 (1993) 2584-2587
15. National Committee for Clinical Laboratory Standards, 2000. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 5th ed., Approved Standerd M7-A5, NCCLS, Villanova, Pa, USA.
16. Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob. Agents Chemother. 33 (1989) 1831-1836
17. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264 (1994) 382-388
18. Omri A., and Ravaoarinoro M. Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations on Gram-negative and Gram-positive bacteria. Int. J. Antimicrob. Agents 7 (1996) 9-14
19. Omri A., Suntres Z.E., and Shek P.N. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol. 64 (2002) 1407-1413
20. Pinto-Alphandary H., Andremont A., and Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents 13 (2000) 155-168
21. Puglisi G., Fresta M., Mazzone G., Furneri P.M., and Tempera G. Formulation parameters of fluoroquinolone-loaded liposomes and in vitro antimicrobial activity. Int. J. Pharm. 118 (1995) 65-76
22. Putman M., van Veen H.W., and Konings W.N. Molecular properties of bacterial multidrug transporters. Microbiol. Mol. Biol. Rev. 64 (2000) 672-693
23. Quinn J.P., Dudek E.J., DiVincenzo C.A., Lucks D.A., and Lerner S.A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis. 154 (1986) 289-294
24. Ralston E., Hjelmenland L.M., Klausner R.D., Weinstein J.N., and Blumenthal R. Carboxyfluorescein as a probe for liposome-cell interactions: effect of impurities, and purification of the dye. Biochim. Biophis. Acta 619 (1981) 133-137
25. Revathi G., Puri J., and Jain B.K. Bacteriology of burns. Burns 4 (1998) 347-359
26. Sachetelli S., Khalil H., Chen T., Beaulac C., Senechal S., and Lagace J. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim. Biophys. Acta 1463 (2000) 254-266
27. Salem I.I., and Duzgunes N. Efficacies of cyclodextrin-complexed and liposome-encapsulated clarithromycin against Mycobacterium avium complex infection in human macrophages. Int. J. Pharm. 250 (2003) 403-414
28. Schiffelers R., Storm G., and Bakker-Woudenberg I.A.J.M. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 48 (2001) 333-344
29. Senda K., Arakowa Y., Nakashima K., Ito H., Ichiyama S., Shimokata K., Kato N., and Ohta M. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob. Agents Chemother. 40 (1996) 349-353
30. Siami G., Christou N., and Eiseman I. Tack, and the clinafloxacin severe skin and soft tissue infections study group, clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections. Antimicrob. Agents Chemother. 45 (2001) 525-531
31. Sihorkar V., and Vyas S.P. Biofilm consortia on biomedical and biological surfaces: delivery and targeting strategies. Pharm. Res. 18 (2001) 1247-1254
32. Stewart J.C.M. Anal. Biochem. 104 (1959) 10-14
33. Wong J.P., Yang H., Blasetti K.L., Schnell G., Conley J., and Schofield L.N. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Rel. 92 (2003) 265-273